Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

(OT): KSQ Therapeutics is working on gene-edited TIL cell therapies for solid tumours. KSQ-001, is the lead single-edited TIL program, which applied the CRISPRomics platform to T-cells to discover the top genes to inactivate with CRISPR/Cas9 with the goal of maximising the ability of tumour-targeting T-cells to destroy solid tumours.